Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BEAZER HOMES USA INCBZH · Entity 5036 | Director | November 17, 2025 | November 18, 2025 |
| EQUIFAX INCEFX · Entity 3235 | EVP, Chief Legal Officer | February 11, 2025 | February 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BEAZER HOMES USA INC
Report date November 17, 2025 · Filed November 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,116 |
Reported balance
After 2025-11-17 transaction · row 1
1 source rowRow 1 · 2025-11-17 · Grant · Acquired 7,199 · Balance 23,116 F1: Restricted stock award scheduled to vest on the first anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock award scheduled to vest on the first anniversary of grant date.
EQUIFAX INC
Report date February 11, 2025 · Filed February 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,175 |
Last balance in matching sequence
After 2025-02-11 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-02-11 · Grant · Acquired 2,710 · Balance 17,202 F1: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Row 2 · 2025-02-11 · Tax withholding · Disposed 2,027 · Balance 15,175 F1: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2022 Filed Oct 28, 2022 20:12 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 510 | $163.35 | $83,308.25 |
DisclosureSEC source: 0001225208-22-011214 · doc4.xml · nonDerivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,049 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 8/24/2022. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $162.94 to $163.91, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| October 26, 2022 Filed Oct 28, 2022 20:12 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 483 | $162.25 | $78,364.72 |
DisclosureSEC source: 0001225208-22-011214 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,559 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 8/24/2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $161.79 to $162.67, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:11 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 9,017 | $212.24 | $1,913,768.08 |
DisclosureSEC source: 0001225208-22-003264 · doc4.xml · nonDerivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,011 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:11 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 17,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003264 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,028 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 22:33 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 7,109 | $0.00 Strike: $225.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002187 · doc4.xml · derivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,109 Underlying: Common Stock · 7,109 shares Expires 2032-02-11 F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 2/11/2023. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 22:33 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 1,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002187 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,531 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/11/2025. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:42 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionStock Option/Right to Buy · Derivative | 2,761 | $0.00 Strike: $191.44 | $0.00 |
DisclosureSEC source: 0001225208-22-000214 · doc4.xml · derivative · entry 5 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,523 Underlying: Common Stock · 2,761 shares Expires 2026-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in three equal annual increments beginning 2/21/2021. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:42 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionStock Option/Right to Buy · Derivative | 2,188 | $0.00 Strike: $175.48 | $0.00 |
DisclosureSEC source: 0001225208-22-000214 · doc4.xml · derivative · entry 4 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,378 Underlying: Common Stock · 2,188 shares Expires 2026-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in three equal annual increments beginning 2/21/2021. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:42 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 3,950 | $291.54 | $1,151,583.00 |
DisclosureSEC source: 0001225208-22-000214 · doc4.xml · nonDerivative · entry 3 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,753 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:42 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionCommon Stock | 2,188 | $175.48 | $383,950.24 |
DisclosureSEC source: 0001225208-22-000214 · doc4.xml · nonDerivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:42 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionCommon Stock | 2,761 | $191.44 | $528,565.84 |
DisclosureSEC source: 0001225208-22-000214 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionStock Option/Right to Buy · Derivative | 16,196 | $0.00 Strike: $123.49 | $0.00 |
DisclosureSEC source: 0001225208-21-011701 · doc4.xml · derivative · entry 5 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,196 shares Expires 2028-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 5/27/2021. F6 · derivative.exercise_date: The option vested in three equal annual increments beginning 7/27/2019. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 12,722 | $257.12 | $3,271,041.20 |
DisclosureSEC source: 0001225208-21-011701 · doc4.xml · nonDerivative · entry 4 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,738 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 5/27/2021. F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $256.655 to $257.61, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 10,623 | $256.16 | $2,721,137.75 |
DisclosureSEC source: 0001225208-21-011701 · doc4.xml · nonDerivative · entry 3 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,460 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 5/27/2021. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $255.645 to $256.62, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 1,755 | $257.73 | $452,321.06 |
DisclosureSEC source: 0001225208-21-011701 · doc4.xml · nonDerivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,083 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 5/27/2021. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $257.63 to $258.50, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:13 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionCommon Stock | 16,196 | $123.49 | $2,000,044.04 |
DisclosureSEC source: 0001225208-21-011701 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 5/27/2021. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 20:18 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 1,887 | $258.29 | $487,393.23 |
DisclosureSEC source: 0001225208-21-010925 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,642 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionStock Option/Right to Buy · Derivative | 8,859 | $0.00 Strike: $121.35 | $0.00 |
DisclosureSEC source: 0001225208-21-008588 · doc4.xml · derivative · entry 5 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,859 shares Expires 2028-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in three equal annual increments beginning 3/5/2019. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionStock Option/Right to Buy · Derivative | 8,279 | $0.00 Strike: $129.93 | $0.00 |
DisclosureSEC source: 0001225208-21-008588 · doc4.xml · derivative · entry 4 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,279 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in three equal annual increments beginning 2/16/2018. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 12,734 | $235.94 | $3,004,459.96 |
DisclosureSEC source: 0001225208-21-008588 · doc4.xml · nonDerivative · entry 3 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,512 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionCommon Stock | 8,279 | $129.93 | $1,075,690.47 |
DisclosureSEC source: 0001225208-21-008588 · doc4.xml · nonDerivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:11 UTC | EQUIFAX INC EFX · Entity 3235 | Exercise / conversionCommon Stock | 8,859 | $121.35 | $1,075,039.65 |
DisclosureSEC source: 0001225208-21-008588 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:09 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 3,570 | $238.38 | $851,017.67 |
DisclosureSEC source: 0001225208-21-008119 · doc4.xml · nonDerivative · entry 3 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,108 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/25/2021. F5 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $237.725 to $238.71, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:09 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 1,361 | $237.20 | $322,822.80 |
DisclosureSEC source: 0001225208-21-008119 · doc4.xml · nonDerivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,678 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/25/2021. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $236.69 to $237.64, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:09 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 1,203 | $236.02 | $283,928.81 |
DisclosureSEC source: 0001225208-21-008119 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,039 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on 2/25/2021. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $235.62 to $236.375, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:20 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 4,430 | $169.75 | $751,992.50 |
DisclosureSEC source: 0001225208-21-004920 · doc4.xml · nonDerivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,215 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:20 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 7,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004920 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,645 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:23 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 6,773 | $0.00 Strike: $177.19 | $0.00 |
DisclosureSEC source: 0001225208-21-002796 · doc4.xml · derivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,773 Underlying: Common Stock · 6,773 shares Expires 2031-02-12 F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 2/12/2022. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 22:23 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 1,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002796 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,122 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/12/2024. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:16 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 7,670 | $147.94 | $1,134,707.47 |
DisclosureSEC source: 0001225208-20-007576 · doc4.xml · nonDerivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,357 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on February 25, 2020. F4 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $147.355 to $148.335, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:16 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 4,830 | $148.93 | $719,336.73 |
DisclosureSEC source: 0001225208-20-007576 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,027 F1 · kind: The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on February 25, 2020. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $148.38 to $149.72, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:55 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 6,566 | $0.00 Strike: $175.48 | $0.00 |
DisclosureSEC source: 0001225208-20-003454 · doc4.xml · derivative · entry 3 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,566 Underlying: Common Stock · 6,566 shares Expires 2026-02-21 F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 2/21/2021. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:55 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 8,284 | $0.00 Strike: $191.44 | $0.00 |
DisclosureSEC source: 0001225208-20-003454 · doc4.xml · derivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,284 Underlying: Common Stock · 8,284 shares Expires 2026-02-21 F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 2/21/2021. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:55 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 1,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003454 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,828 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/21/2023. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 21:12 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 565 | $161.88 | $91,462.20 |
DisclosureSEC source: 0001225208-20-003094 · doc4.xml · nonDerivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,947 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 21:12 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 1,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003094 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,512 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 22:03 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 967 | $159.63 | $154,362.21 |
DisclosureSEC source: 0001225208-20-002781 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,260 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 01:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 13,150 | $0.00 Strike: $127.37 | $0.00 |
DisclosureSEC source: 0001225208-19-003793 · doc4.xml · derivative · entry 4 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,150 Underlying: Common Stock · 13,150 shares Expires 2025-02-22 F3 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 01:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 15,899 | $0.00 Strike: $138.45 | $0.00 |
DisclosureSEC source: 0001225208-19-003793 · doc4.xml · derivative · entry 3 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,899 Underlying: Common Stock · 15,899 shares Expires 2025-02-22 F3 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 01:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 19,172 | $0.00 Strike: $149.53 | $0.00 |
DisclosureSEC source: 0001225208-19-003793 · doc4.xml · derivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,172 Underlying: Common Stock · 19,172 shares Expires 2025-02-22 F3 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 01:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 2,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003793 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,099 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/22/2022. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 21:50 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 2,310 | $109.32 | $252,529.20 |
DisclosureSEC source: 0001225208-19-003071 · doc4.xml · nonDerivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,673 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 21:50 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 1,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003071 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,983 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| July 27, 2018 Filed Jul 31, 2018 20:52 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 16,196 | $0.00 Strike: $123.49 | $0.00 |
DisclosureSEC source: 0001225208-18-012075 · doc4.xml · derivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,196 Underlying: Common Stock · 16,196 shares Expires 2028-07-27 F3 · derivative.exercise_date: Special equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 7/27/2019. Read SEC document |
| July 27, 2018 Filed Jul 31, 2018 20:52 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 4,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-012075 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,109 F1 · security: Special equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 7/27/2021. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:19 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 8,859 | $0.00 Strike: $121.35 | $0.00 |
DisclosureSEC source: 0001225208-18-005688 · doc4.xml · derivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · CVP, CLO & CS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,859 Underlying: Common Stock · 8,859 shares Expires 2028-03-05 F3 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 3/5/2019. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:19 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 2,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-005688 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · CVP, CLO & CS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,033 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 3/5/2021. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 19, 2018 Filed Feb 21, 2018 22:36 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 7,129 | $117.46 | $837,372.34 |
DisclosureSEC source: 0001225208-18-003601 · doc4.xml · nonDerivative · entry 2 KELLEY JOHN J III · CIK 0001562224 · CVP, CLO & CS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,818 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in the corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 19, 2018 Filed Feb 21, 2018 22:36 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 12,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003601 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · CVP, CLO & CS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,947 F1 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in the corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 20:59 UTC | EQUIFAX INC EFX · Entity 3235 | SaleCommon Stock | 8,500 | $130.85 | $1,112,200.35 |
DisclosureSEC source: 0001225208-17-005278 · doc4.xml · nonDerivative · entry 1 KELLEY JOHN J III · CIK 0001562224 · CVP, CLO & CS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,787 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $130.81 to $130.96, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.